{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:13:54Z","timestamp":1793211234218,"version":"4.5.0"},"reference-count":114,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2010,1,1]],"date-time":"2010-01-01T00:00:00Z","timestamp":1262304000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2010,1]]},"DOI":"10.1038\/sj.bjc.6605498","type":"journal-article","created":{"date-parts":[[2010,1,5]],"date-time":"2010-01-05T16:21:28Z","timestamp":1262708488000},"page":"301-315","source":"Crossref","is-referenced-by-count":200,"title":["Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes"],"prefix":"10.1038","volume":"102","author":[{"given":"J","family":"Glaspy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Crawford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Vansteenkiste","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Henry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Bowers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J A","family":"Berlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Tomita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Bridges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Ludwig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,1,5]]},"reference":[{"key":"BF6605498_CR1","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1038\/sj.bjc.6603481","volume":"95","author":"M Aapro","year":"2006","unstructured":"Aapro M, Coiffier B, Dunst J, Osterborg A, Burger HU (2006) Effect of treatment with epoetin beta on short-term tumour progression and survival in anaemic patients with cancer: a meta-analysis. Br J Cancer 95: 1467\u20131473","journal-title":"Br J Cancer"},{"key":"BF6605498_CR2","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1200\/JCO.2007.11.5378","volume":"26","author":"M Aapro","year":"2008","unstructured":"Aapro M, Leonard RC, Barnadas A, Marangolo M, Untch M, Malamos N, Mayordomo J, Reichert D, Pedrini JL, Ukarma L, Scherhag A, Burger HU (2008a) Effect of once-weekly epoetin beta on survival in patients with metastatic breast cancer receiving anthracycline- and\/or taxane-based chemotherapy: results of the Breast Cancer-Anemia and the Value of Erythropoietin (BRAVE) study. J Clin Oncol 26: 592\u2013598","journal-title":"J Clin Oncol"},{"key":"BF6605498_CR3","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/sj.bjc.6604408","volume":"99","author":"M Aapro","year":"2008","unstructured":"Aapro M, Scherhag A, Burger HU (2008b) Effect of treatment with epoetin-beta on survival, tumour progression and thromboembolic events in patients with cancer: an updated meta-analysis of 12 randomised controlled studies including 2301 patients. Br J Cancer 99: 14\u201322","journal-title":"Br J Cancer"},{"issue":"Suppl 2","key":"BF6605498_CR4","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/S0959-8049(05)80281-3","volume":"29A","author":"R Abels","year":"1993","unstructured":"Abels R (1993) Erythropoietin for anaemia in cancer patients. Eur J Cancer 29A (Suppl 2): S2\u2013S8","journal-title":"Eur J Cancer"},{"key":"BF6605498_CR5","first-page":"3561","volume":"61","author":"G Acs","year":"2001","unstructured":"Acs G, Acs P, Beckwith SM, Pitts RL, Clements E, Wong K, Verma A (2001) Erythropoietin and erythropoietin receptor expression in human cancer. Cancer Res 61: 3561\u20133565","journal-title":"Cancer Res"},{"key":"BF6605498_CR6","doi-asserted-by":"crossref","unstructured":"Amato A, Pescatori M (2006) Perioperative blood transfusions for the recurrence of colorectal cancer. Cochrane Database Syst Rev 25 (1): CD005033","DOI":"10.1002\/14651858.CD005033.pub2"},{"key":"#cr-split#-BF6605498_CR7.1","unstructured":"2. Amgen (2007) Amgen announces interim results of Aranesp\u00ae 'PREPARE' study in breast cancer patients (Amgen press release). Nov 30, 2007"},{"key":"#cr-split#-BF6605498_CR7.2","unstructured":"3. Available from: http:\/\/www.ext.amgen.com\/media\/media_pr_detail.jsp?year=2007&releaseID=1083091 [Accessed February 29, 2008]"},{"key":"BF6605498_CR8","volume-title":"Aranesp\u00ae(Darbepoetin alfa) Package Insert","author":"Amgen","year":"2009","unstructured":"Amgen (2009) Aranesp\u00ae(Darbepoetin alfa) Package Insert. Amgen Inc., Thousand Oaks, CA"},{"key":"BF6605498_CR9","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1200\/JCO.2004.08.119","volume":"22","author":"M Auerbach","year":"2004","unstructured":"Auerbach M, Ballard H, Trout JR, McIlwain M, Ackerman A, Bahrain H, Balan S, Barker L, Rana J (2004) Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial. J Clin Oncol 22: 1301\u20131307","journal-title":"J Clin Oncol"},{"key":"BF6605498_CR10","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1159\/000067766","volume":"64","author":"A Bamias","year":"2003","unstructured":"Bamias A, Aravantinos G, Kalofonos C, Timotheadou N, Siafaka V, Vlahou I, Janinis D, Pectasides D, Pavlidis N, Fountzilas G (2003) Prevention of anemia in patients with solid tumors receiving platinum-based chemotherapy by recombinant human erythropoietin (rHuEpo): a prospective, open label, randomized trial by the Hellenic Cooperative Oncology Group. Oncology 64: 102\u2013110","journal-title":"Oncology"},{"key":"BF6605498_CR11","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1532\/IJH97.04120","volume":"80","author":"JA Barbara","year":"2004","unstructured":"Barbara JA (2004) The rationale for pathogen-inactivation treatment of blood components. Int J Hematol 80: 311\u2013316","journal-title":"Int J Hematol"},{"key":"BF6605498_CR12","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/S0140-6736(97)10018-6","volume":"351","author":"JA Baron","year":"1998","unstructured":"Baron JA, Gridley G, Weiderpass E, Nyren O, Linet M (1998) Venous thromboembolism and cancer. Lancet 351: 1077\u20131080","journal-title":"Lancet"},{"key":"BF6605498_CR13","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1200\/JCO.2006.10.4620","volume":"26","author":"L Bastit","year":"2008","unstructured":"Bastit L, Vandebroek A, Altintas S, Gaede B, Pinter T, Suto TS, Mossman TW, Smith KE, Vansteenkiste JF (2008) Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alpha administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. J Clin Oncol 26: 1611\u20131618","journal-title":"J Clin Oncol"},{"key":"BF6605498_CR14","first-page":"2855","volume":"300","author":"CL Bennett","year":"2008","unstructured":"Bennett CL, Henke M, Lai SY (2008a) Erythropoiesis-stimulating agents in the treatment of cancer-associated anemia \u2013 Reply. JAMA 300: 2855\u20132857","journal-title":"JAMA"},{"key":"BF6605498_CR15","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1001\/jama.299.8.914","volume":"299","author":"CL Bennett","year":"2008","unstructured":"Bennett CL, Silver SM, Djulbegovic B, Samaras AT, Blau CA, Gleason KJ, Barnato SE, Elverman KM, Courtney DM, McKoy JM, Edwards BJ, Tigue CC, Raisch DW, Yarnold PR, Dorr DA, Kuzel TM, Tallman MS, Trifilio SM, West DP, Lai SY, Henke M (2008b) Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 299: 914\u2013924","journal-title":"JAMA"},{"key":"BF6605498_CR16","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1056\/NEJM199808273390903","volume":"339","author":"A Besarab","year":"1998","unstructured":"Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, Schwab SJ, Goodkin DA (1998) The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339: 584\u2013590","journal-title":"N Engl J Med"},{"key":"BF6605498_CR17","first-page":"Abstract 477PD","volume":"15","author":"J-U Blohmer","year":"2004","unstructured":"Blohmer J-U, Wurschmidt F, Petry U, Weise G, Sehouli J, Kimming R, Dressler P, Kentenich H, Kohls A, Lichtenegger W (2004) Results with sequential adjuvant chemo-radiotherapy with vs without epoetin alfa for patients with high-risk cervical cancer: results of a prospective, randomized, open and controlled AGO- and NOGGO-intergroup study. Ann Oncol 15: Abstract 477PD","journal-title":"Ann Oncol"},{"key":"BF6605498_CR18","first-page":"2854","volume":"300","author":"J Bohlius","year":"2008","unstructured":"Bohlius J, Engert A, Schwarzer G (2008) Erythropoiesis-stimulating agents in the treatment of cancer-associated anemia. JAMA 300: 2854\u20132855; author reply 2855-2857","journal-title":"JAMA"},{"key":"BF6605498_CR19","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1093\/jnci\/dji087","volume":"97","author":"J Bohlius","year":"2005","unstructured":"Bohlius J, Langensiepen S, Schwarzer G, Seidenfeld J, Piper M, Bennett C, Engert A (2005) Recombinant human erythropoietin and overall survival in cancer patients: results of a comprehensive meta-analysis. J Natl Cancer Inst 97: 489\u2013498","journal-title":"J Natl Cancer Inst"},{"key":"BF6605498_CR20","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1016\/S0140-6736(09)60502-X","volume":"373","author":"J Bohlius","year":"2009","unstructured":"Bohlius J, Schmidlin K, Brillant C, Schwarzer G, Trelle S, Seidenfeld J, Zwahlen M, Clarke M, Weingart O, Kluge S, Piper M, Rades D, Steensma DP, Djulbegovic B, Fey MF, Ray-Coquard I, Machtay M, Moebus V, Thomas G, Untch M, Schumacher M, Egger M, Engert A (2009) Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet 373: 1532\u20131542","journal-title":"Lancet"},{"key":"BF6605498_CR21","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1093\/jnci\/djj189","volume":"98","author":"J Bohlius","year":"2006","unstructured":"Bohlius J, Wilson J, Seidenfeld J, Piper M, Schwarzer G, Sandercock J, Trelle S, Weingart O, Bayliss S, Djulbegovic B, Bennett CL, Langensiepen S, Hyde C, Engert A (2006) Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst 98: 708\u2013714","journal-title":"J Natl Cancer Inst"},{"key":"BF6605498_CR22","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.ejca.2006.10.014","volume":"43","author":"C Bokemeyer","year":"2007","unstructured":"Bokemeyer C, Aapro MS, Courdi A, Foubert J, Link H, Osterborg A, Repetto L, Soubeyran P (2007) EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur J Cancer 43: 258\u2013270","journal-title":"Eur J Cancer"},{"key":"BF6605498_CR23","first-page":"479","volume":"26","author":"M Boogaerts","year":"2006","unstructured":"Boogaerts M, Oberhoff C, Ten Bokkel Huinink W, Nowrousian MR, Hayward CR, Burger HU (2006) Epoetin beta (NeoRecormon) therapy in patients with solid tumours receiving platinum and non-platinum chemotherapy: a meta-analysis. Anticancer Res 26: 479\u2013484","journal-title":"Anticancer Res"},{"key":"BF6605498_CR24","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1634\/stemcells.2006-0687","volume":"25","author":"WM Brown","year":"2007","unstructured":"Brown WM, Maxwell P, Graham AN, Yakkundi A, Dunlop EA, Shi Z, Johnston PG, Lappin TR (2007) Erythropoietin receptor expression in non-small cell lung carcinoma: a question of antibody specificity. Stem Cells 25: 718\u2013722","journal-title":"Stem Cells"},{"key":"BF6605498_CR25","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1200\/JCO.1994.12.5.1058","volume":"12","author":"S Cascinu","year":"1994","unstructured":"Cascinu S, Fedeli A, Del Ferro E, Luzi Fedeli S, Catalano G (1994) Recombinant human erythropoietin treatment in cisplatin-associated anemia: a randomized, double-blind trial with placebo. J Clin Oncol 12: 1058\u20131062","journal-title":"J Clin Oncol"},{"key":"BF6605498_CR26","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1093\/jnci\/85.10.801","volume":"85","author":"DC Case Jr","year":"1993","unstructured":"Case Jr DC., Bukowski RM, Carey RW, Fishkin EH, Henry DH, Jacobson RJ, Jones SE, Keller AM, Kugler JW, Nichols CR, Salmon SE, Silver RT, Storniolo AM, Wampler GL, Dooley CM, Larholt KM, Nelson RA, Abels RI (1993) Recombinant human erythropoietin therapy for anemic cancer patients on combination chemotherapy. J Natl Cancer Inst 85: 801\u2013806","journal-title":"J Natl Cancer Inst"},{"key":"BF6605498_CR27","doi-asserted-by":"crossref","first-page":"4446","DOI":"10.1182\/blood.V86.12.4446.bloodjournal86124446","volume":"86","author":"M Cazzola","year":"1995","unstructured":"Cazzola M, Messinger D, Battistel V, Bron D, Cimino R, Enller-Ziegler L, Essers U, Greil R, Grossi A, Jager G, LeMevel A, Najman A, Silingardi V, Spriano M, van Hoof A, Ehmer B (1995) Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin's lymphoma: dose finding and identification of predictors of response. Blood 86: 4446\u20134453","journal-title":"Blood"},{"key":"BF6605498_CR28","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1093\/annonc\/mdg167","volume":"14","author":"D Cella","year":"2003","unstructured":"Cella D, Dobrez D, Glaspy J (2003) Control of cancer-related anemia with erythropoietic agents: a review of evidence for improved quality of life and clinical outcomes. Ann Oncol 14: 511\u2013519","journal-title":"Ann Oncol"},{"key":"BF6605498_CR29","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1200\/JCO.2004.12.027","volume":"23","author":"J Chang","year":"2005","unstructured":"Chang J, Couture F, Young S, McWatters KL, Lau CY (2005) Weekly epoetin alfa maintains hemoglobin, improves quality of life, and reduces transfusion in breast cancer patients receiving chemotherapy. J Clin Oncol 23: 2597\u20132605","journal-title":"J Clin Oncol"},{"key":"BF6605498_CR30","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1634\/theoncologist.12-6-727","volume":"12","author":"V Charu","year":"2007","unstructured":"Charu V, Belani CP, Gill AN, Bhatt M, Tomita D, Rossi G, Ben-Jacob A (2007) Efficacy and safety of every-2-week darbepoetin alfa in patients with anemia of cancer: a controlled, randomized, open-label phase II trial. Oncologist 12: 727\u2013737","journal-title":"Oncologist"},{"key":"BF6605498_CR31","unstructured":"Coiffier B, Boogaerts M, Kainz C, Group EBQW, Group EBPW (2001) Impact of epopetin beta versus standard care on quality of life in patients with malignant disease. Paper presented at: The 6th Annual Meeting of the European Haematology Association; June 21\u201324, 2001; Frankfurt, Germany"},{"key":"BF6605498_CR32","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1634\/theoncologist.5-5-353","volume":"5","author":"GA Curt","year":"2000","unstructured":"Curt GA, Breitbart W, Cella D, Groopman JE, Horning SJ, Itri LM, Johnson DH, Miaskowski C, Scherr SL, Portenoy RK, Vogelzang NJ (2000) Impact of cancer-related fatigue on the lives of patients: new findings from the Fatigue Coalition. Oncologist 5: 353\u2013360","journal-title":"Oncologist"},{"key":"BF6605498_CR33","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1046\/j.1365-2141.2001.02715.x","volume":"113","author":"F Dammacco","year":"2001","unstructured":"Dammacco F, Castoldi G, Rodjer S (2001) Efficacy of epoetin alfa in the treatment of anaemia of multiple myeloma. Br J Haematol 113: 172\u2013179","journal-title":"Br J Haematol"},{"key":"#cr-split#-BF6605498_CR34.1","unstructured":"5. Debus J, Hindermann S, Morr H, Mezger J, Sebastian M, Angermund R, Drings P (2006) Epoetin alfa"},{"key":"#cr-split#-BF6605498_CR34.2","unstructured":"6. (EPO) and survival in patients with non-resectable NSCLC - Interim results. Presented at the German Medical Sciences Meeting, Berlin 2006. Available from: http:\/\/www.egms.de\/en\/meetings\/dkk2006\/06dkk257.shtml [Accessed 29 May 2008]"},{"key":"BF6605498_CR35","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1200\/JCO.1997.15.7.2715","volume":"15","author":"L Del Mastro","year":"1997","unstructured":"Del Mastro L, Venturini M, Lionetto R, Garrone O, Melioli G, Pasquetti W, Sertoli MR, Bertelli G, Canavese G, Costantini M, Rosso R (1997) Randomized phase III trial evaluating the role of erythropoietin in the prevention of chemotherapy-induced anemia. J Clin Oncol 15: 2715\u20132721","journal-title":"J Clin Oncol"},{"key":"BF6605498_CR36","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.1998.16.10.3412","volume":"16","author":"GD Demetri","year":"1998","unstructured":"Demetri GD, Kris M, Wade J, Degos L, Cella D (1998) Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group. J Clin Oncol 16: 3412\u20133425","journal-title":"J Clin Oncol"},{"key":"BF6605498_CR37","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1002\/(SICI)1097-0142(19991001)86:7<1362::AID-CNCR36>3.0.CO;2-T","volume":"86","author":"FR Dunphy","year":"1999","unstructured":"Dunphy FR, Harrison BR, Dunleavy TL, Rodriguez JJ, Hilton JG, Boyd JH (1999) Erythropoietin reduces anemia and transfusions: a randomized trial with or without erythropoietin during chemotherapy. Cancer 86: 1362\u20131367","journal-title":"Cancer"},{"key":"BF6605498_CR38","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1136\/bmj.315.7121.1533","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Smith GD, Phillips AN (1997) Meta-analysis: principles and procedures. BMJ 315: 1533\u20131537","journal-title":"BMJ"},{"key":"BF6605498_CR39","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1182\/blood-2005-10-4066","volume":"107","author":"S Elliott","year":"2006","unstructured":"Elliott S, Busse L, Bass MB, Lu H, Sarosi I, Sinclair AM, Spahr C, Um M, Van G, Begley CG (2006) Anti-Epo receptor antibodies do not predict Epo receptor expression. Blood 107: 1892\u20131895","journal-title":"Blood"},{"key":"#cr-split#-BF6605498_CR40.1","unstructured":"7. eMC (2008) electronic Medicines Compendium"},{"key":"#cr-split#-BF6605498_CR40.2","unstructured":"8. (eMC) website. Available from: http:\/\/emc.medicines.org.uk [Accessed October 29, 2008]"},{"key":"BF6605498_CR41","unstructured":"EMEA (2008) European public assessment reports for authorised medicinal products for human use. European Medicines Agency website. Available from: http:\/\/www.emea.europa.eu\/htms\/human\/epar\/a.htm [Accessed October 29, 2008]"},{"key":"#cr-split#-BF6605498_CR42.1","unstructured":"10. Engert A (2007) On behalf of the German Hodgkin Study Group. Role of erythropoetin (EPO) in patients with Hodgkin lymphoma. Paper presented at The 7th International Symposium on Hodgkin Lymphoma"},{"key":"#cr-split#-BF6605498_CR42.2","unstructured":"11. Engert A (2007) On behalf of the German Hodgkin Study Group. Role of erythropoetin"},{"key":"#cr-split#-BF6605498_CR42.3","unstructured":"12. (EPO) in patients with Hodgkin lymphoma. Paper presented at The 7th International Symposium on Hodgkin Lymphoma; November 3-7, 2007; Cologne, Germany"},{"key":"BF6605498_CR43","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/pros.20310","volume":"66","author":"L Feldman","year":"2006","unstructured":"Feldman L, Wang Y, Rhim JS, Bhattacharya N, Loda M, Sytkowski AJ (2006) Erythropoietin stimulates growth and STAT5 phosphorylation in human prostate epithelial and prostate cancer cells. Prostate 66: 135\u2013145","journal-title":"Prostate"},{"key":"BF6605498_CR44","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1200\/JCO.2001.19.11.2875","volume":"19","author":"JL Gabrilove","year":"2001","unstructured":"Gabrilove JL, Cleeland CS, Livingston RB, Sarokhan B, Winer E, Einhorn LH (2001) Clinical evaluation of once weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times weekly dosing. J Clin Oncol 19: 2875\u20132882","journal-title":"J Clin Oncol"},{"key":"BF6605498_CR45","doi-asserted-by":"crossref","first-page":"338S","DOI":"10.1378\/chest.126.3_suppl.338S","volume":"126","author":"WH Geerts","year":"2004","unstructured":"Geerts WH, Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW, Ray JG (2004) Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126: 338S\u2013400S","journal-title":"Chest"},{"key":"BF6605498_CR46","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1200\/JCO.1997.15.3.1218","volume":"15","author":"J Glaspy","year":"1997","unstructured":"Glaspy J, Bukowski R, Steinberg D, Taylor C, Tchekmedyian S, Vadhan-Raj S (1997) Impact of therapy with epoetin alfa on clinical outcomes in patients with non-myeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group. J Clin Oncol 15: 1218\u20131234","journal-title":"J Clin Oncol"},{"key":"BF6605498_CR47","doi-asserted-by":"crossref","first-page":"Abstract 1304","DOI":"10.1182\/blood.V108.11.1304.1304","volume":"108","author":"DH Gordon","year":"2006","unstructured":"Gordon DH, Nichols G, Ben-Jacob A, Lam H, Lillie T, Miller C (2006) Treating anemia of cancer with darbepoetin alfa administered every 4 weeks: Final results from a phase 2, randomized, double-blind, placebo-controlled study in cancer patients not receiving chemotherapy and\/or radiotherapy. Blood 108: Abstract 1304","journal-title":"Blood"},{"key":"BF6605498_CR48","doi-asserted-by":"crossref","first-page":"S53","DOI":"10.1016\/S0169-5002(05)80288-0","volume":"49","author":"G Goss","year":"2005","unstructured":"Goss G, Feld R, Bezjak A, Perry G, Melosky B, Smith C, Snee M, Plante R, Lau C (2005) Impact of maintaining Hb with epoetin alfa on time to progression (TTP), overall survival (OS), quality of life (QOL), and transfusion reduction in limited disease SCLC patients. Lung Cancer 49: S53, Abstract O-154","journal-title":"Lung Cancer"},{"key":"BF6605498_CR49","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1093\/jnci\/91.19.1616","volume":"91","author":"JE Groopman","year":"1999","unstructured":"Groopman JE, Itri LM (1999) Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 91: 1616\u20131634","journal-title":"J Natl Cancer Inst"},{"key":"BF6605498_CR50","doi-asserted-by":"crossref","first-page":"9377","DOI":"10.1200\/JCO.2005.01.8507","volume":"23","author":"T Grote","year":"2005","unstructured":"Grote T, Yeilding AL, Castillo R, Butler D, Fishkin E, Henry DH, DeLeo M, Fink K, Sullivan DJ (2005) Efficacy and safety analysis of epoetin alfa in patients with small-cell lung cancer: a randomized, double-blind, placebo-controlled trial. J Clin Oncol 23: 9377\u20139386","journal-title":"J Clin Oncol"},{"key":"BF6605498_CR51","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1046\/j.1365-2141.2003.04448.x","volume":"122","author":"M Hedenus","year":"2003","unstructured":"Hedenus M, Adriansson M, San Miguel J, Kramer MH, Schipperus MR, Juvonen E, Taylor K, Belch A, Altes A, Martinelli G, Watson D, Matcham J, Rossi G, Littlewood TJ (2003) Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study. Br J Haematol 122: 394\u2013403","journal-title":"Br J Haematol"},{"key":"BF6605498_CR52","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1046\/j.1365-2141.2002.03774.x","volume":"119","author":"M Hedenus","year":"2002","unstructured":"Hedenus M, Hansen S, Taylor K, Arthur C, Emmerich B, Dewey C, Watson D, Rossi G, Osterborg A (2002) Randomized, dose-finding study of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies. Br J Haematol 119: 79\u201386","journal-title":"Br J Haematol"},{"key":"BF6605498_CR53","doi-asserted-by":"crossref","first-page":"6941","DOI":"10.1200\/JCO.2005.03.434","volume":"23","author":"M Hedenus","year":"2005","unstructured":"Hedenus M, Vansteenkiste J, Kotasek D, Austin M, Amado RG (2005) Darbepoetin alfa for the treatment of chemotherapy-induced anemia: disease progression and survival analysis from four randomized, double-blind, placebo-controlled trials. J Clin Oncol 23: 6941\u20136948","journal-title":"J Clin Oncol"},{"key":"BF6605498_CR54","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0140-6736(03)14567-9","volume":"362","author":"M Henke","year":"2003","unstructured":"Henke M, Laszig R, Rube C, Schafer U, Haase KD, Schilcher B, Mose S, Beer KT, Burger U, Dougherty C, Frommhold H (2003) Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 362: 1255\u20131260","journal-title":"Lancet"},{"key":"BF6605498_CR55","first-page":"252","volume":"1","author":"DH Henry","year":"1995","unstructured":"Henry DH, Brooks Jr BJ., Case Jr DC., Fishkin E, Jacobson R, Keller AM, Kugler J, Moore J, Silver RT, Storniolo AM, Abels RI, Gordon DS, Nelson R, Larholt K, Bryant E, Rudnick S (1995) Recombinant human erythropoietin therapy for anemic cancer patients receiving cisplatin chemotherapy. Cancer J Sci Am 1: 252\u2013260","journal-title":"Cancer J Sci Am"},{"key":"BF6605498_CR56","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.2215\/CJN.04601007","volume":"3","author":"RD Kilpatrick","year":"2008","unstructured":"Kilpatrick RD, Critchlow CW, Fishbane S, Besarab A, Stehman-Breen C, Krishnan M, Bradbury BD (2008) Greater epoetin alfa responsiveness is associated with improved survival in hemodialysis patients. Clin J Am Soc Nephrol 3: 1077\u20131083","journal-title":"Clin J Am Soc Nephrol"},{"issue":"Suppl 7A","key":"BF6605498_CR57","doi-asserted-by":"crossref","first-page":"11S","DOI":"10.1016\/j.amjmed.2003.12.008","volume":"116","author":"K Knight","year":"2004","unstructured":"Knight K, Wade S, Balducci L (2004) Prevalence and outcomes of anemia in cancer: a systematic review of the literature. Am J Med 116 (Suppl 7A): 11S\u201326S","journal-title":"Am J Med"},{"key":"BF6605498_CR58","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1016\/S0959-8049(03)00456-8","volume":"39","author":"D Kotasek","year":"2003","unstructured":"Kotasek D, Steger G, Faught W, Underhill C, Poulsen E, Colowick AB, Rossi G, Mackey J (2003) Darbepoetin alfa administered every 3 weeks alleviates anaemia in patients with solid tumours receiving chemotherapy; results of a double-blind, placebo-controlled, randomised study. Eur J Cancer 39: 2026\u20132034","journal-title":"Eur J Cancer"},{"key":"BF6605498_CR59","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1006\/gyno.1997.4675","volume":"65","author":"C Kurz","year":"1997","unstructured":"Kurz C, Marth C, Windbichler G, Lahousen M, Medl M, Vavra N, Sevelda P (1997) Erythropoietin treatment under polychemotherapy in patients with gynecologic malignancies: a prospective, randomized, double-blind placebo-controlled multicenter study. Gynecol Oncol 65: 461\u2013466","journal-title":"Gynecol Oncol"},{"key":"BF6605498_CR60","doi-asserted-by":"crossref","first-page":"4442","DOI":"10.1038\/sj.onc.1208635","volume":"24","author":"SY Lai","year":"2005","unstructured":"Lai SY, Childs EE, Xi S, Coppelli FM, Gooding WE, Wells A, Ferris RL, Grandis JR (2005) Erythropoietin-mediated activation of JAK-STAT signaling contributes to cellular invasion in head and neck squamous cell carcinoma. Oncogene 24: 4442\u20134449","journal-title":"Oncogene"},{"key":"BF6605498_CR61","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1002\/ijc.23201","volume":"122","author":"M Laugsch","year":"2008","unstructured":"Laugsch M, Metzen E, Svensson T, Depping R, Jelkmann W (2008) Lack of functional erythropoietin receptors of cancer cell lines. Int J Cancer 122: 1005\u20131011","journal-title":"Int J Cancer"},{"key":"BF6605498_CR62","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0305-7372(02)00044-0","volume":"28","author":"AY Lee","year":"2002","unstructured":"Lee AY (2002) Cancer and thromboembolic disease: pathogenic mechanisms. Cancer Treat Rev 28: 137\u2013140","journal-title":"Cancer Treat Rev"},{"key":"BF6605498_CR63","doi-asserted-by":"crossref","first-page":"5960","DOI":"10.1200\/JCO.2005.06.150","volume":"23","author":"B Leyland-Jones","year":"2005","unstructured":"Leyland-Jones B, Semiglazov V, Pawlicki M, Pienkowski T, Tjulandin S, Manikhas G, Makhson A, Roth A, Dodwell D, Baselga J, Biakhov M, Valuckas K, Voznyi E, Liu X, Vercammen E (2005) Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol 23: 5960\u20135972","journal-title":"J Clin Oncol"},{"key":"BF6605498_CR64","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1200\/JCO.2001.19.11.2865","volume":"19","author":"TJ Littlewood","year":"2001","unstructured":"Littlewood TJ, Bajetta E, Nortier JW, Vercammen E, Rapoport B (2001) Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 19: 2865\u20132874","journal-title":"J Clin Oncol"},{"key":"BF6605498_CR65","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1378\/chest.126.1.249","volume":"126","author":"MR Looney","year":"2004","unstructured":"Looney MR, Gropper MA, Matthay MA (2004) Transfusion-related acute lung injury: a review. Chest 126: 249\u2013258","journal-title":"Chest"},{"key":"BF6605498_CR66","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1016\/j.ejca.2004.06.019","volume":"40","author":"H Ludwig","year":"2004","unstructured":"Ludwig H, Van Belle S, Barrett-Lee P, Birgegard G, Bokemeyer C, Gascon P, Kosmidis P, Krzakowski M, Nortier J, Olmi P, Schneider M, Schrijvers D (2004) The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 40: 2293\u20132306","journal-title":"Eur J Cancer"},{"key":"BF6605498_CR67","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.ijrobp.2007.04.063","volume":"69","author":"M Machtay","year":"2007","unstructured":"Machtay M, Pajak TF, Suntharalingam M, Shenouda G, Hershock D, Stripp DC, Cmelak AJ, Schulsinger A, Fu KK (2007) Radiotherapy with or without erythropoietin for anemic patients with head and neck cancer: a randomized trial of the Radiation Therapy Oncology Group (RTOG 99-03). Int J Radiat Oncol Biol Phys 69: 1008\u20131017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"BF6605498_CR68","doi-asserted-by":"crossref","first-page":"S74","DOI":"10.1016\/S0169-5002(03)91911-8","volume":"41","author":"R Milroy","year":"2003","unstructured":"Milroy R, Scagliotti G, van den Berg PM, Galanis NE, Gomez RG, Greil R, Krzakowski M (2003) Early intervention with epoetin alfa maintains hemoglobin (HB) in advanced non-small-cell lung cancer (NSCLC) patients. Lung Cancer 41: S74","journal-title":"Lung Cancer"},{"key":"BF6605498_CR69","doi-asserted-by":"crossref","unstructured":"Minton O, Stone P, Richardson A, Sharpe M, Hotopf M (2008) Drug therapy for the management of cancer related fatigue. Cochrane Database Syst Rev 23 (1): CD006704","DOI":"10.1002\/14651858.CD006704.pub2"},{"key":"BF6605498_CR70","doi-asserted-by":"crossref","first-page":"Abstract 569","DOI":"10.1200\/jco.2007.25.18_suppl.569","volume":"25","author":"V Moebus","year":"2007","unstructured":"Moebus V, Lueck H, Thomssen C, Harbeck N, Nitz U, Kreienberg R, Jackisch C, Schneeweiss A, Huober J, du Bois A, Untch M (2007) The impact of epoetin-alpha on anemia, red blood cell (RBC) transfusions, and survival in breast cancer patients (pts) treated with dose-dense sequential chemotherapy: Mature results of an AGO phase III study (ETC trial). J Clin Oncol 25: Abstract 569","journal-title":"J Clin Oncol"},{"key":"BF6605498_CR71","first-page":"3495","volume":"25","author":"K Mystakidou","year":"2005","unstructured":"Mystakidou K, Kalaidopoulou O, Katsouda E, Parpa E, Kouskouni E, Chondros C, Tsiatas ML, Vlahos L (2005) Evaluation of epoetin supplemented with oral iron in patients with solid malignancies and chronic anemia not receiving anticancer treatment. Anticancer Res 25: 3495\u20133500","journal-title":"Anticancer Res"},{"key":"BF6605498_CR72","doi-asserted-by":"crossref","first-page":"439","DOI":"10.3816\/CBC.2005.n.002","volume":"5","author":"JA O\u2019Shaughnessy","year":"2005","unstructured":"O\u2019Shaughnessy JA, Vukelja SJ, Holmes FA, Savin M, Jones M, Royall D, George M, Von Hoff D (2005) Feasibility of quantifying the effects of epoetin alfa therapy on cognitive function in women with breast cancer undergoing adjuvant or neoadjuvant chemotherapy. Clin Breast Cancer 5: 439\u2013446","journal-title":"Clin Breast Cancer"},{"key":"BF6605498_CR73","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1023\/A:1008296622469","volume":"9","author":"C Oberhoff","year":"1998","unstructured":"Oberhoff C, Neri B, Amadori D, Petry KU, Gamucci T, Rebmann U, Nowrousian MR, Voigtmann R, Monfardini S, Armand JP, Herrmann R, Netter-Pinon J, Tubiana-Mathieu N, Zwierzina H (1998) Recombinant human erythropoietin in the treatment of chemotherapy-induced anemia and prevention of transfusion requirement associated with solid tumors: a randomized, controlled study. Ann Oncol 9: 255\u2013260","journal-title":"Ann Oncol"},{"key":"BF6605498_CR74","unstructured":"ODAC (2008) Amgen Inc. in collaboration with Johnson & Johnson Pharmaceutical Research and Development, L.L.C.Background Information. For The Oncologic Drugs Advisory Comittee (ODAC) Meeting 13 March 2008. Available from: http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/08\/briefing\/2008-4345b2-00-FDA-index.htm [Accessed March 21, 2008]"},{"key":"BF6605498_CR75","volume-title":"Procrit\u00ae (Epoetin alfa) Package Insert","author":"Ortho","year":"2009","unstructured":"Ortho (2009) Procrit\u00ae (Epoetin alfa) Package Insert. Centocor Ortho Biotech Inc.: L.P., Raritan, NJ"},{"key":"BF6605498_CR76","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.ejca.2006.10.012","volume":"43","author":"A Osterborg","year":"2007","unstructured":"Osterborg A, Aapro M, Cornes P, Haselbeck A, Hayward CR, Jelkmann W (2007) Preclinical studies of erythropoietin receptor expression in tumour cells: impact on clinical use of erythropoietic proteins to correct cancer-related anaemia. Eur J Cancer 43: 510\u2013519","journal-title":"Eur J Cancer"},{"key":"BF6605498_CR77","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1182\/blood.V87.7.2675.bloodjournal8772675","volume":"87","author":"A Osterborg","year":"1996","unstructured":"Osterborg A, Boogaerts MA, Cimino R, Essers U, Holowiecki J, Juliusson G, Jager G, Najman A, Peest D (1996) Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin's lymphoma--a randomized multicenter study. The European Study Group of Erythropoietin (Epoetin Beta) Treatment in Multiple Myeloma and Non-Hodgkin's Lymphoma. Blood 87: 2675\u20132682","journal-title":"Blood"},{"key":"BF6605498_CR78","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/j.1365-2141.2005.05440.x","volume":"129","author":"A Osterborg","year":"2005","unstructured":"Osterborg A, Brandberg Y, Hedenus M (2005) Impact of epoetin-beta on survival of patients with lymphoproliferative malignancies: long-term follow up of a large randomized study. Br J Haematol 129: 206\u2013209","journal-title":"Br J Haematol"},{"key":"BF6605498_CR79","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S1359-6349(07)70099-X","volume":"4","author":"J Overgaard","year":"2007","unstructured":"Overgaard J, Hoff C, Sand Hansen H, Specht L, Overgaard M, Grau C, Andersen E, Johansen J, Andersen L, Evensen J (2007) Randomized study of the importance of novel erythropoiesis stimulating protein (Aranesp\u00ae) for the effect of radiotherapy in patients with primary squamous cell carcinoma of the head and neck (HNSCC)- the Danish Head and Neck Cancer Group DAHANCA 10 randomized trial. Eur J Cancer 4: 7 (Abstract 628)","journal-title":"Eur J Cancer"},{"key":"BF6605498_CR80","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1111\/j.1365-2141.1995.tb08374.x","volume":"89","author":"GA Pangalis","year":"1995","unstructured":"Pangalis GA, Poziopoulos C, Angelopoulou MK, Siakantaris MP, Panayiotidis P (1995) Effective treatment of disease-related anaemia in B-chronic lymphocytic leukaemia patients with recombinant human erythropoietin. Br J Haematol 89: 627\u2013629","journal-title":"Br J Haematol"},{"key":"BF6605498_CR81","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1200\/JCO.2007.15.0748","volume":"26","author":"R Pirker","year":"2008","unstructured":"Pirker R, Ramlau RA, Schuette W, Zatloukal P, Ferreira I, Lillie T, Vansteenkiste JF (2008) Safety and efficacy of darbepoetin alfa in previously untreated extensive-stage small-cell lung cancer treated with platinum plus etoposide. J Clin Oncol 26: 2342\u20132349","journal-title":"J Clin Oncol"},{"key":"BF6605498_CR82","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1093\/annonc\/13s50168","volume":"13","author":"P Pronzato","year":"2002","unstructured":"Pronzato P, Cortesi E, van der Rijt C, Moreno-Nogueira A, Raimundo D, Ostler P, Bols A, Rosso R (2002) Early intervention with epoetin alfa in breast cancer (BC) patients (pts) undergoing chemotherapy (CT): results of a randomized, multicenter, phase IIIb study (EPO-INT-47 Study Group). Ann Oncol 13: 168","journal-title":"Ann Oncol"},{"key":"BF6605498_CR83","doi-asserted-by":"crossref","first-page":"3583","DOI":"10.1200\/JCO.2005.03.4371","volume":"24","author":"BI Razzouk","year":"2006","unstructured":"Razzouk BI, Hord JD, Hockenberry M, Hinds PS, Feusner J, Williams D, Rackoff WR (2006) Double-blind, placebo-controlled study of quality of life, hematologic end points, and safety of weekly epoetin alfa in children with cancer receiving myelosuppressive chemotherapy. J Clin Oncol 24: 3583\u20133589","journal-title":"J Clin Oncol"},{"key":"BF6605498_CR84","doi-asserted-by":"crossref","first-page":"526a","DOI":"10.1182\/blood.V84.2.526.526","volume":"84","author":"E Rose","year":"1994","unstructured":"Rose E, Rai K, Revicki D, Brown R, Reblando J (1994) Clinical and health status assessments in anemic chronic lymphocytic leukemia (CLL) patients treated with epoetin alfa (EPO). Blood 84: 526a (Abstract 2091)","journal-title":"Blood"},{"key":"BF6605498_CR85","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.clinthera.2006.06.003","volume":"28","author":"SD Ross","year":"2006","unstructured":"Ross SD, Allen IE, Henry DH, Seaman C, Sercus B, Goodnough LT (2006) Clinical benefits and risks associated with epoetin and darbepoetin in patients with chemotherapy-induced anemia: a systematic review of the literature. Clin Ther 28: 801\u2013831","journal-title":"Clin Ther"},{"key":"BF6605498_CR86","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1016\/j.ejca.2005.03.024","volume":"41","author":"JH Savonije","year":"2005","unstructured":"Savonije JH, van Groeningen CJ, van Bochove A, Honkoop AH, van Felius CL, Wormhoudt LW, Giaccone G (2005) Effects of early intervention with epoetin alfa on transfusion requirement, hemoglobin level and survival during platinum-based chemotherapy: results of a multicenter randomised controlled trial. Eur J Cancer 41: 1560\u20131569","journal-title":"Eur J Cancer"},{"key":"BF6605498_CR87","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.2146\/ajhp060601","volume":"64","author":"RN Schwartz","year":"2007","unstructured":"Schwartz RN (2007) Anemia in patients with cancer: incidence, causes, impact, management, and use of treatment guidelines and protocols. Am J Health Syst Pharm 64: S5\u201313","journal-title":"Am J Health Syst Pharm"},{"key":"BF6605498_CR88","volume-title":"Comparative Effectiveness of Epoetin and Darbepoetin for Managing Anemia in Patients Undergoing Cancer Treatment","author":"J Seidenfeld","year":"2006","unstructured":"Seidenfeld J, Piper M, Bohlius J, Weingart O, Trelle S, Engert A, Skoetz N, Schwarzer G, Wilson J, Brunskill S, Hyde C, Bonnell C, Ziegler KM, Aronson N (2006) Comparative Effectiveness of Epoetin and Darbepoetin for Managing Anemia in Patients Undergoing Cancer Treatment Comparative Effectiveness Review No. 3. (Prepared by Blue Cross and Blue Shield Association Technology Evaluation Center Evidence-based Practice Center under Contract No. 290-02-0026). May 2006. Available from: http:\/\/effectivehealthcare.ahrq.gov\/repFiles\/EPO%20Final.pdf . Agency for Healthcare Research and Quality: Rockville, MD, [Accessed February 27, 2008]"},{"key":"BF6605498_CR89","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1038\/sj.bjc.6604220","volume":"98","author":"AM Sinclair","year":"2008","unstructured":"Sinclair AM, Rogers N, Busse L, Archibeque I, Brown W, Kassner PD, Watson JEV, Arnold GE, Nguyen KCQ, Powers S, Elliott S (2008) Erythropoietin receptor transcription is neither elevated nor predictive of surface expression in human tumour cells. Br J Cancer 98: 1059\u20131067","journal-title":"Br J Cancer"},{"key":"BF6605498_CR90","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1002\/cncr.22832","volume":"110","author":"AM Sinclair","year":"2007","unstructured":"Sinclair AM, Todd MD, Forsythe K, Knox SJ, Elliott S, Begley CG (2007) Expression and function of erythropoietin receptors in tumors: implications for the use of erythropoiesis-stimulating agents in cancer patients. Cancer 110: 477\u2013488","journal-title":"Cancer"},{"key":"BF6605498_CR91","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1056\/NEJMoa065485","volume":"355","author":"AK Singh","year":"2006","unstructured":"Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D (2006) Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355: 2085\u20132098","journal-title":"N Engl J Med"},{"key":"BF6605498_CR92","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1200\/JCO.2007.14.2885","volume":"26","author":"RE Smith Jr","year":"2008","unstructured":"Smith Jr RE., Aapro MS, Ludwig H, Pinter T, Smakal M, Ciuleanu TE, Chen L, Lillie T, Glaspy JA (2008) Darbepoetin alfa for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study. J Clin Oncol 26: 1040\u20131050","journal-title":"J Clin Oncol"},{"key":"BF6605498_CR93","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1038\/sj.bjc.6600994","volume":"88","author":"RE Smith Jr","year":"2003","unstructured":"Smith Jr RE., Tchekmedyian NS, Chan D, Meza LA, Northfelt DW, Patel R, Austin M, Colowick AB, Rossi G, Glaspy J (2003) A dose- and schedule-finding study of darbepoetin alpha for the treatment of chronic anaemia of cancer. Br J Cancer 88: 1851\u20131858","journal-title":"Br J Cancer"},{"key":"BF6605498_CR94","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.2146\/ajhp070244","volume":"64","author":"RK Spence","year":"2007","unstructured":"Spence RK (2007) Medical and economic impact of anemia in hospitalized patients. Am J Health Syst Pharm 64: S3\u201310","journal-title":"Am J Health Syst Pharm"},{"key":"BF6605498_CR95","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1111\/j.1525-1438.2007.01032.x","volume":"18","author":"HG Strauss","year":"2008","unstructured":"Strauss HG, Haensgen G, Dunst J, Hayward CR, Burger HU, Scherhag A, Koelbl H (2008) Effects of anemia correction with epoetin beta in patients receiving radiochemotherapy for advanced cervical cancer. Int J Gynecol Cancer 18: 515\u2013524","journal-title":"Int J Gynecol Cancer"},{"key":"BF6605498_CR96","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1046\/j.1365-2141.2000.01828.x","volume":"108","author":"A Takeshita","year":"2000","unstructured":"Takeshita A, Shinjo K, Higuchi M, Miyawaki S, Takemoto Y, Kishimoto Y, Saito K, Takuchi H, Kuriyama K, Kimura Y, Asou N, Takahashi M, Hotta T, Kanamaru A, Ueda R, Ohno R (2000) Quantitative expression of erythropoietin receptor (EPO-R) on acute leukaemia cells: relationships between the amount of EPO-R and CD phenotypes, in vitro proliferative response, the amount of other cytokine receptors and clinical prognosis. Japan Adult Leukaemia Study Group. Br J Haematol 108: 55\u201363","journal-title":"Br J Haematol"},{"key":"BF6605498_CR97","doi-asserted-by":"crossref","first-page":"Abstract 3556","DOI":"10.1182\/blood.V106.11.3556.3556","volume":"106","author":"K Taylor","year":"2005","unstructured":"Taylor K, Ganly P, Charu V, DiBenedetto J, Kracht K, Rossi G, Hernandez E (2005) Randomized, double-blind, placebo-controlled study of darbepoetin alfa every 3 weeks for the treatment of chemotherapy-induced anemia. Blood 106: Abstract 3556","journal-title":"Blood"},{"key":"BF6605498_CR98","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1007\/BF02821936","volume":"15","author":"WW ten Bokkel Huinink","year":"1998","unstructured":"ten Bokkel Huinink WW, de Swart CA, van Toorn DW, Morack G, Breed WP, Hillen HF, van der Hoeven JJ, Reed NS, Fairlamb DJ, Chan SY, Godfrey KA, Kristensen GB, van Tinteren H, Ehmer B (1998) Controlled multicentre study of the influence of subcutaneous recombinant human erythropoietin on anaemia and transfusion dependency in patients with ovarian carcinoma treated with platinum-based chemotherapy. Med Oncol 15: 174\u2013182","journal-title":"Med Oncol"},{"key":"BF6605498_CR99","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/sj.bjc.6690369","volume":"80","author":"N Thatcher","year":"1999","unstructured":"Thatcher N, De Campos ES, Bell DR, Steward WP, Varghese G, Morant R, Vansteenkiste JF, Rosso R, Ewers SB, Sundal E, Schatzmann E, Stocker H (1999) Epoetin alpha prevents anaemia and reduces transfusion requirements in patients undergoing primarily platinum-based chemotherapy for small cell lung cancer. Br J Cancer 80: 396\u2013402","journal-title":"Br J Cancer"},{"key":"BF6605498_CR100","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.ygyno.2007.10.011","volume":"108","author":"G Thomas","year":"2008","unstructured":"Thomas G, Ali S, Hoebers FJ, Darcy KM, Rodgers WH, Patel M, Abulafia O, Lucci III JA, Begg AC (2008) Phase III trial to evaluate the efficacy of maintaining hemoglobin levels above 12.0\u2009g\/dl with erythropoietin vs above 10.0\u2009g\/dl without erythropoietin in anemic patients receiving concurrent radiation and cisplatin for cervical cancer. Gynecol Oncol 108: 317\u2013325","journal-title":"Gynecol Oncol"},{"key":"BF6605498_CR101","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1182\/blood.V95.4.1175.004k51_1175_1179","volume":"95","author":"JA Thompson","year":"2000","unstructured":"Thompson JA, Gilliland DG, Prchal JT, Bennett JM, Larholt K, Nelson RA, Rose EH, Dugan MH (2000) Effect of recombinant human erythropoietin combined with granulocyte\/macrophage colony-stimulating factor in the treatment of patients with myelodysplastic syndrome. GM\/EPO MDS Study Group. Blood 95: 1175\u20131179","journal-title":"Blood"},{"key":"BF6605498_CR102","first-page":"Abstract 1558","volume":"19","author":"N Throuvalas","year":"2000","unstructured":"Throuvalas N, Antonadou D, Boufi M, Lavey R, Malamos N (2000) Erythropoietin decreases transfusion requirements during radiotherapy. J Clin Oncol 19: Abstract 1558","journal-title":"J Clin Oncol"},{"key":"BF6605498_CR103","doi-asserted-by":"crossref","first-page":"E62","DOI":"10.1503\/cmaj.090470","volume":"180","author":"M Tonelli","year":"2009","unstructured":"Tonelli M, Hemmelgarn B, Reiman T, Manns B, Reaume MN, Lloyd A, Wiebe N, Klarenbach S (2009) Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: a meta-analysis. CMAJ 180: E62\u2013E71","journal-title":"CMAJ"},{"key":"BF6605498_CR104","doi-asserted-by":"crossref","first-page":"Abstract 2915","DOI":"10.1182\/blood.V104.11.2915.2915","volume":"104","author":"S Vadhan-Raj","year":"2004","unstructured":"Vadhan-Raj S, Skibber JM, Crane C, Bueso-Ramos CE, Rodriguez-Bigas MA, Feig BW, Lin EH, Ajani JA, Collard M, Johnson MM, Hamilton SR, JanJan N (2004) Randomized, double-blind, placebo-controlled trial of epoetin alfa (Procrit) in patients with rectal and gastric cancer undergoing chemo-radiotherapy (CT\/RT) followed by surgery: early termination of the trial due to increased incidence of thrombo-embolic events (TEE). Blood 104: Abstract 2915","journal-title":"Blood"},{"key":"BF6605498_CR105","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1093\/jnci\/94.16.1211","volume":"94","author":"J Vansteenkiste","year":"2002","unstructured":"Vansteenkiste J, Pirker R, Massuti B, Barata F, Font A, Fiegl M, Siena S, Gateley J, Tomita D, Colowick AB, Musil J (2002) Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 94: 1211\u20131220","journal-title":"J Natl Cancer Inst"},{"key":"BF6605498_CR106","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1046\/j.1523-1755.2000.00211.x","volume":"58","author":"C Westenfelder","year":"2000","unstructured":"Westenfelder C, Baranowski RL (2000) Erythropoietin stimulates proliferation of human renal carcinoma cells. Kidney Int 58: 647\u2013657","journal-title":"Kidney Int"},{"key":"BF6605498_CR107","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/sj.bjc.6603004","volume":"94","author":"PM Wilkinson","year":"2006","unstructured":"Wilkinson PM, Antonopoulos M, Lahousen M, Lind M, Kosmidis P (2006) Epoetin alfa in platinum-treated ovarian cancer patients: results of a multinational, multicentre, randomised trial. Br J Cancer 94: 947\u2013954","journal-title":"Br J Cancer"},{"key":"BF6605498_CR108","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1200\/JCO.2004.10.020","volume":"23","author":"TE Witzig","year":"2005","unstructured":"Witzig TE, Silberstein PT, Loprinzi CL, Sloan JA, Novotny PJ, Mailliard JA, Rowland KM, Alberts SR, Krook JE, Levitt R, Morton RF (2005) Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy. J Clin Oncol 23: 2606\u20132617","journal-title":"J Clin Oncol"},{"key":"BF6605498_CR109","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1200\/JCO.2006.07.1514","volume":"25","author":"JR Wright","year":"2007","unstructured":"Wright JR, Ung YC, Julian JA, Pritchard KI, Whelan TJ, Smith C, Szechtman B, Roa W, Mulroy L, Rudinskas L, Gagnon B, Okawara GS, Levine MN (2007) Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. J Clin Oncol 25: 1027\u20131032","journal-title":"J Clin Oncol"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/6605498.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6605498","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6605498.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T08:43:32Z","timestamp":1684399412000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/6605498"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,1]]},"references-count":114,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,1]]}},"alternative-id":["BF6605498"],"URL":"https:\/\/doi.org\/10.1038\/sj.bjc.6605498","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,1]]}}}